{"title":"透析患者的肾脏临床药学服务和结果:范围综述","authors":"Rebecca Livori BPharm (Hons), GradCertPharmPrac, GradCertHlthSysMgmt, MSc (RenalMedicine), FANZCAP (Neph, MedSafety), MAdPha, Catherine Shaji BPharm (Hons)/MPharm, MAdPha, Dao Gia Nguyen Tran BPharm (Hons)/MPharm, MAdPha, Carla Scuderi BPharm, MClinPharm, PhD, FANZCAP (Neph, Lead&Mgt), FAdPha, Renee Dimond BPharm (Hons), MClinPharm, GradCertEdDes, FANZCAP (Paeds, Edu), MAdPha, Adam Livori BAppSci (NucMed), BPharm (Hons), MClinPharm, FCSANZ, FANZCAP (Cardiol, Res), FAdPha","doi":"10.1002/jppr.70006","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (<i>n</i> = 29), pharmacist inclusion in the multidisciplinary team (<i>n</i> = 22), extended pharmacist consultation (<i>n</i> = 20), and targeted adherence counselling (<i>n</i> = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"55 4","pages":"271-286"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70006","citationCount":"0","resultStr":"{\"title\":\"Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review\",\"authors\":\"Rebecca Livori BPharm (Hons), GradCertPharmPrac, GradCertHlthSysMgmt, MSc (RenalMedicine), FANZCAP (Neph, MedSafety), MAdPha, Catherine Shaji BPharm (Hons)/MPharm, MAdPha, Dao Gia Nguyen Tran BPharm (Hons)/MPharm, MAdPha, Carla Scuderi BPharm, MClinPharm, PhD, FANZCAP (Neph, Lead&Mgt), FAdPha, Renee Dimond BPharm (Hons), MClinPharm, GradCertEdDes, FANZCAP (Paeds, Edu), MAdPha, Adam Livori BAppSci (NucMed), BPharm (Hons), MClinPharm, FCSANZ, FANZCAP (Cardiol, Res), FAdPha\",\"doi\":\"10.1002/jppr.70006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (<i>n</i> = 29), pharmacist inclusion in the multidisciplinary team (<i>n</i> = 22), extended pharmacist consultation (<i>n</i> = 20), and targeted adherence counselling (<i>n</i> = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.</p>\\n </section>\\n </div>\",\"PeriodicalId\":16795,\"journal\":{\"name\":\"Journal of Pharmacy Practice and Research\",\"volume\":\"55 4\",\"pages\":\"271-286\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70006\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Practice and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jppr.70006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.70006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review
Background
People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.
Aim
This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.
Design
This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.
Results
Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (n = 29), pharmacist inclusion in the multidisciplinary team (n = 22), extended pharmacist consultation (n = 20), and targeted adherence counselling (n = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.
Conclusion
The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.
期刊介绍:
The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.